Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Lifted to "Hold" by Zacks Research

Key Points

• Zacks Research upgraded Vanda Pharmaceuticals from “strong sell” to “hold.” Across analysts, the stock has a “Moderate Buy” consensus and a $13.50 average price target.
• Shares opened at $3.59, close to their 52-week low of $3.57 and well below the 52-week high of $9.94.
• Vanda reported a quarterly loss of $0.37 per share, better than the $0.68 loss analysts expected; revenue of $69.81 million also modestly exceeded forecasts.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a research note issued to investors on Wednesday, Zacks reports.

Other research analysts also recently issued research reports about the stock. Oppenheimer assumed coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, September 23rd. They set an "outperform" rating and a $10.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating on shares of Vanda Pharmaceuticals in a report on Monday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a research report on Thursday, October 15th. B. Riley Financial reissued a "buy" rating and set a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th. Finally, Wall Street Zen upgraded Vanda Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, October 31st. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $13.50.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ:VNDA opened at $3.59 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.53 and a current ratio of 1.54. The firm has a fifty day moving average price of $4.66 and a 200 day moving average price of $6.14. Vanda Pharmaceuticals has a fifty-two week low of $3.57 and a fifty-two week high of $9.94. The firm has a market cap of $217.09 million, a price-to-earnings ratio of -0.78 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its earnings results on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.31. The company had revenue of $69.81 million during the quarter, compared to analysts' expectations of $69.20 million. Vanda Pharmaceuticals had a negative net margin of 119.87% and a negative return on equity of 62.70%. As a group, sell-side analysts expect that Vanda Pharmaceuticals will post -2.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter worth about $46,841,000. Monaco Asset Management SAM purchased a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter valued at about $1,354,000. State Street Corp lifted its holdings in shares of Vanda Pharmaceuticals by 16.6% in the 2nd quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company's stock valued at $21,520,000 after acquiring an additional 500,843 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Vanda Pharmaceuticals in the 2nd quarter valued at about $1,317,000. Finally, Arrowstreet Capital Limited Partnership purchased a new position in Vanda Pharmaceuticals in the first quarter worth about $1,668,000. 88.14% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Vanda Pharmaceuticals

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Director Charles Cliff Duncan bought a combined 10,000 shares from November 3–5 for approximately $38,069, increasing his ownership. SEC ownership filing
• Neutral Sentiment: HC Wainwright maintained its Buy rating and raised its 2026 EPS estimate to a loss of $2.45 from a loss of $3.03, including a narrower projected Q4 loss.
• Negative Sentiment: HC Wainwright lowered estimates for Q2–Q4 2027 and cut its full-year 2027 EPS forecast to a loss of $1.02 from a loss of $0.94, signaling a less favorable outlook for those periods.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda's marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.